PTED Versus Radiofrequency Ablation for Lumbar Disc Herniation
Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Aug 14, 2018
Trial Information
Current as of May 15, 2025
Unknown status
Keywords
ClinConnect Summary
Please see the Eligibility Criteria or Outcome Measures sections.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Lumbar intervertebral disc herniation has been treated with conservative treatment of \> for 3 months, or can only temporarily improve symptoms to relieve pain, but can not be maintained for a long time, aged between 18 and 60;
- • The symptoms and signs of lumbar intervertebral disc herniation are obviously consistent with those of CT or MRI;
- • The protrusion size was \< 8.0mm, and imaging examination showed the protrusion of intervertebral disc, mild or moderate protrusion, without calcification, dissociation, and osseous spinal stenosis;
- • Patients have a strong desire to treat, and understand radiofrequency thermal coagulation ablation and intervertebral endoscopic treatment of possible risk patients;
- • Conservative treatment is ineffective and the surgical treatment is rejected.
- Exclusion Criteria:
- • The non-inclusion or prominent calcification, dissociation, dissociation and consolidation of vertebral canal stenosis or caudal syndrome in the rupture of the fibrous ring and posterior longitudinal ligament;
- • Patients with spinal fractures, tumors and intervertebral discs have skin infections that affect the puncture;
- • The combination of mental illness or cognitive dysfunction;
- • Patients with serious diseases such as active tuberculosis or heart, lung, liver and kidney;
- • Abnormal bleeding or coagulation function caused by various reasons;
- • Menstrual period and lactation period;
- • No informed consent is signed.
About First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of Xi'an Jiaotong University is a leading medical institution renowned for its commitment to advancing healthcare through clinical research and innovative treatment approaches. As a prominent academic hospital in China, it integrates clinical practice, education, and research, fostering a collaborative environment that enables the development of cutting-edge therapies and medical technologies. With a multidisciplinary team of experts and state-of-the-art facilities, the hospital plays a pivotal role in conducting high-quality clinical trials that aim to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Trial Officials
Yingang Zhang, MD
Principal Investigator
First Affiliated Hospital, Medical College of Xi'an Jiaotong University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials